So they can now be even further wrong than they have been since they started coverage. Whoever follows their recomondation sure has lost a lot of money. You know the stock is down 8% in 52 weeks and the stock market is up more than that? It equates to quite a loss on your money if you had it in AVNR. I think resistance is at $2.89 and support is way down at $2.57, that ain't good. More money losing coming. A lot of losing before this stock ever gets to $12!
Thank you for that much appreciated.
In the event you happen across Thomas Wei of Jefferies CC report would you be kind enough to put it up big and bold I would not want to miss it.
Very best regards.
Sr Falconi - Jefferies did file a report and remained on Hold with a $3 pt, as expected. What is interesting to note however, is that in their AVNR financial spreadsheet they have added a line item called "License Agreements" and are modeling an amount of $50.0 million for Q4 2013 FY. This is on top of sales revenues of $20.97 million for a total of $70.97 million in revenues for the quarter. It appears that they are expecting upfront payments for an EU partnership to be made in that quarter. No other analyst that I see is doing same.
BTW, I have seen most of the reports of the various analysts covering AVNR. I have tried to post excerpts from several but they are being rejected by Yahoo as they are likely encrypted. All analysts (with the exception of Wei) are maintaining their Buy or Outperform ratings. They are quite positive about AVNR, Nuedexta, the study/trial results and in general about the future for the company.
Sentiment: Strong Buy